STATEMENT OF NEED
Of the estimated 74,680 new cases of non-Hodgkin lymphoma each year in the United States, approximately 35% are follicular lymphoma (FL), an indolent, difficult-to-treat B-cell malignancy. Most patients are diagnosed at an average age of 65 years. Despite the introduction of novel therapies during the past decade, complications such as delayed presentation and treatment and evolving disease subtypes continue to hamper patient outcomes, and multiple recurrences with available therapies are common. Currently, allogeneic hematopoietic stem cell transplant is the only curative therapeutic modality for relapsed/refractory disease. However, the risk for comorbidities and secondary cancers limit the utility of this treatment upfront. Further research is required to determine the optimal timing and role of transplant and novel therapies to keep the remission rate among FL patients high and durable.
Hematology/oncology physicians, oncology advanced practitioners, oncology nurses, and other health care professionals involved in the treatment of patients with FL.
Upon completion of this activity, participants should be able to:
Christopher R. Flowers, MD, MS (Chairperson)
Professor of Hematology and Oncology
There is no fee to participate in or claim CME/CE credit for this activity.
Jointly Provided by
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and i3 Health. Postgraduate Institute for Medicine is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this live activity for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The maximum number of hours awarded for this Continuing Nursing Education activity is 1.2 contact hours. Activity has been approved for 0.5 contact hours of pharmacotherapy credit for Advanced Practice Registered Nurses.
Provider approved by the California Board of Registered Nursing, Provider Number 13485, for 1.2 contact hours.
The program content has been reviewed by the Oncology Nursing Certification Corporation (ONCC) and is acceptable for recertification points.
ONCC review is only for designating content to be used for recertification points and is not for CNE accreditation. CNE programs must be formally approved for contact hours by an acceptable accreditor/approver of nursing CE to be used for recertification by ONCC. If the CNE provider fails to obtain formal approval to award contact hours by an acceptable accrediting/approval body, no information related to ONCC recertification may be used in relation to the program.
OCN®, CPHON®, CBCN®, AOCNP®, AOCNS®, and BMTCN® renewal candidates may apply 1 ILNA point toward:
Please note that some of the course content applies to multiple content areas. The numerical value above indicates the maximum amount of points that can be claimed in each domain. The total amount of ILNA points claimed may not exceed the total amount of CNE awarded from this course.
DISCLOSURE OF RELEVANT FINANCIAL INFORMATION WITH COMMERCIAL INTERESTS
Postgraduate Institute for Medicine (PIM) requires instructors, planners, managers and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
Christopher R. Flowers discloses that he has served as a consultant for Abbvie, AstraZeneca, Bayer, Celgene (unpaid), Denovo Biopharma, Genentech/Roche (unpaid), Gilead, Karyopharm, OptumRx, Pharmacyclics/Janssen, and Spectrum. He has also received research support from Abbvie, Acerta, BeiGene, Celgene, Genentech/Roche, Gilead, Janssen Pharmaceutical, Millenium/Takeda, Pharmacyclics, and TG Therapeutics.
Planners and Managers
The PIM planners and managers have nothing to disclose. The i3 Health planners and managers have nothing to disclose.
INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for this activity, participants must:
UNAPPROVED USE DISCLOSURE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Bayer Healthcare Pharmaceuticals, Inc. and Celgene Corporation.